Bluebird Bio Inc
![Bluebird Bio Inc](https://api.admiralmarkets.com/trade_icons/bright-128/BLUE.png)
Closed
0.52 -7.14
Overview
Share price change
24h
Min
0.51
Max
0.53
Income | -72M |
---|---|
Sales | 12M |
EPS | -0.66 |
Profit margin | -578.849 |
EBITDA | -84M |
Recommendations | Buy |
---|---|
12 Months Forecast | +686.79 upside |
Next Earnings | 5 Nov 2024 |
---|
Market Cap | 5.7M 240M |
---|---|
Previous open | 7.66 |
Previous close | 0.52 |
Technical Score
By Trading Central
Confidence
Bearish Evidence
Bluebird Bio Inc Chart
Related News
Peer Comparison
Price change
Bluebird Bio Inc Forecast
Price Target
By TipRanks
686.79% upside
12 Months Forecast
Average 4.17 USD 686.79%
High 6 USD
Low 3 USD
Based on 10 Wall Street analysts offering 12 month price targets forBluebird Bio Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
EBITDA
Operating profit
$
About Bluebird Bio Inc
bluebird bio, Inc. is a biotechnology company. The Company focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. It develops LentiGlobin for sickle cell disease (SCD) as a one-time treatment for patients with SCD, a hereditary blood disorder resulting from a mutation in the ß-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. It builds an integrated product platform with therapeutic in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. Its programs in genetic disease include betibeglogene autotemcel; LentiGlobin gene therapy for sickle cell disease (SCD); and elivaldogene autotemcel. Its programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.